Fe3O4/Polycaprolactone Microneedles with Controlled Drug Delivery and Magnetic Hyperthermia

Cheng, Jiwei; Chen, Gang; Zhu, Yufang

doi:10.22180/na200

Cited by 6 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodegradable Fe3O4/PCL MNs were developed for potential skin cancer treatment with transdermal controlled drug delivery and magnetic hyperthermia [188].…”

Section: Pcl Mnsmentioning

confidence: 99%

Microneedle array systems for long-acting drug delivery

Vora

Moffatt

Tekko

et al. 2021

European Journal of Pharmaceutics and Biopharmaceutics

177

View full text Add to dashboard Cite

“…Biodegradable Fe3O4/PCL MNs were developed for potential skin cancer treatment with transdermal controlled drug delivery and magnetic hyperthermia [188].…”

Section: Pcl Mnsmentioning

confidence: 99%

Microneedle array systems for long-acting drug delivery

Vora

Moffatt

Tekko

et al. 2021

European Journal of Pharmaceutics and Biopharmaceutics

177

View full text Add to dashboard Cite

“…PLGA-based MN arrays were proven to support long-term controlled drug release of hydrophobic pharmaceuticals (Park et al., 2006 ), although their application in the state-of-the-art remains limited (Koyani, 2020 ), as poly( ε -caprolactone)-based (PCL) MN arrays can offer similar properties combining thermostability, and low melting point, resulting in more efficient processability; moreover, its utilization is cost-efficient. Poly( ε -caprolactone)-based MN arrays (Andersen et al., 2018 ) were proven to provide sufficient transdermal delivery toward cosmetic applications (Ko et al., n.d ), skin cancer treatment (Cheng et al., 2017 ) and pH responsive gene delivery (Li et al., 2019 ). Ko et al.…”

Section: Introductionmentioning

confidence: 99%

Photo-crosslinkable polyester microneedles as sustained drug release systems toward hypertrophic scar treatment

Szabó,

De Decker,

Semey

et al. 2024

Drug Delivery

View full text Add to dashboard Cite

Burn injuries can result in a significant inflammatory response, often leading to hypertrophic scarring (HTS). Local drug therapies e.g. corticoid injections are advised to treat HTS, although they are invasive, operator-dependent, extremely painful and do not permit extended drug release. Polymer-based microneedle (MN) arrays can offer a viable alternative to standard care, while allowing for direct, painless dermal drug delivery with tailorable drug release profile. In the current study, we synthesized photo-crosslinkable, acrylate-endcapped urethane-based poly( ε -caprolactone) (AUP-PCL) toward the fabrication of MNs. Physico-chemical characterization ( 1 H-NMR, evaluation of swelling, gel fraction) of the developed polymer was performed and confirmed successful acrylation of PCL-diol. Subsequently, AUP-PCL, and commercially available PCL-based microneedle arrays were fabricated for comparative evaluation of the constructs. Hydrocortisone was chosen as model drug. To enhance the drug release efficiency of the MNs, Brij®35, a nonionic surfactant was exploited. The thermal properties of the MNs were evaluated via differential scanning calorimetry. Compression testing of the arrays confirmed that the MNs stay intact upon applying a load of 7 N, which correlates to the standard dermal insertion force of MNs. The drug release profile of the arrays was evaluated, suggesting that the developed PCL arrays can offer efficient drug delivery for up to two days, while the AUP-PCL arrays can provide a release up to three weeks. Finally, the insertion of MN arrays into skin samples was performed, followed by histological analysis demonstrating the AUP-PCL MNs outperforming the PCL arrays upon providing pyramidical-shaped perforations through the epidermal layer of the skin.

show abstract